{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:28:20Z","timestamp":1755599300006,"version":"3.37.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001807","name":"funda\u00e7\u00e3o de amparo \u00e0 pesquisa do estado de s\u00e3o paulo","doi-asserted-by":"publisher","award":["2012\/51692-7"],"award-info":[{"award-number":["2012\/51692-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"name":"cnpq","award":["428793\/2016-9"],"award-info":[{"award-number":["428793\/2016-9"]}]},{"DOI":"10.13039\/501100018861","name":"inct-fcx","doi-asserted-by":"crossref","award":["2014\/50983-3"],"award-info":[{"award-number":["2014\/50983-3"]}],"id":[{"id":"10.13039\/501100018861","id-type":"DOI","asserted-by":"crossref"}]},{"name":"astrazeneca investigator-initiative grant","award":["ESR 14-10726"],"award-info":[{"award-number":["ESR 14-10726"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Large observational studies have shown that small, dense LDL subfractions are related to atherosclerotic cardiovascular disease. This study assessed the effects of two highly effective lipid-lowering therapies in the atherogenic subclasses of lipoproteins in subjects with ST-segment elevation myocardial infarction (STEMI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients of both sexes admitted with their first myocardial infarction and submitted to pharmacoinvasive strategy (<jats:italic>N<\/jats:italic>\u2009=\u2009101) were included and randomized using a central computerized system to receive a daily dose of simvastatin 40\u2009mg plus ezetimibe 10\u2009mg or rosuvastatin 20\u2009mg for 30\u2009days. Intermediate-density lipoprotein (IDL) and low-density lipoprotein (LDL) subfractions were analysed by polyacrylamide gel electrophoresis (Lipoprint System) on the first (D1) and 30th days (D30) of lipid-lowering therapy. Changes in LDL and IDL subfractions between D1 and D30 were compared between the lipid-lowering therapies (Mann-Whitney U test).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The classic lipid profile was similar in both therapy arms at D1 and D30. At D30, the achievement of lipid goals was comparable between lipid-lowering therapies. Cholesterol content in atherogenic subclasses of LDL (<jats:italic>p<\/jats:italic>\u2009=\u20090.043) and IDL (<jats:italic>p<\/jats:italic>\u2009=\u20090.047) decreased more efficiently with simvastatin plus ezetimibe than with rosuvastatin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Lipid-lowering therapy with simvastatin plus ezetimibe was associated with a better pattern of lipoprotein subfractions than rosuvastatin monotherapy. This finding was noted despite similar effects in the classic lipid profile and may contribute to residual cardiovascular risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>, NCT02428374, registered on 28\/09\/2014.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01559-w","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T17:17:41Z","timestamp":1632935861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Main differences between two highly effective lipid-lowering therapies in subclasses of lipoproteins in patients with acute myocardial infarction"],"prefix":"10.1186","volume":"20","author":[{"given":"Leticia C. S.","family":"Pinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana P. Q.","family":"Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C. O.","family":"Izar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagila R. T.","family":"Damasceno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio M. F.","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina N.","family":"Fran\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Caixeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique T.","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui M. S.","family":"P\u00f3voa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio T.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda S. F.","family":"Bacchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-4598","authenticated-orcid":false,"given":"Francisco A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"issue":"1","key":"1559_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"25","key":"1559_CR2","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1161\/CIR.0000000000000624","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Circulation. 2019;139(25):e1046\u201381. https:\/\/doi.org\/10.1161\/CIR.0000000000000624.","journal-title":"Circulation"},{"issue":"1","key":"1559_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jacc.2013.03.058","volume":"62","author":"AS Kini","year":"2013","unstructured":"Kini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, Sweeny J, et al. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). J Am Coll Cardiol. 2013;62(1):21\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2013.03.058.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1559_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jjcc.2019.08.002","volume":"75","author":"H Yano","year":"2020","unstructured":"Yano H, Horinaka S, Ishimitsu T. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J Cardiol. 2020;75(3):289\u201395. https:\/\/doi.org\/10.1016\/j.jjcc.2019.08.002.","journal-title":"J Cardiol"},{"issue":"41","key":"1559_CR5","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1093\/eurheartj\/eht260","volume":"34","author":"R Puri","year":"2013","unstructured":"Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, et al. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. Eur Heart J. 2013;34(41):3182\u201390. https:\/\/doi.org\/10.1093\/eurheartj\/eht260.","journal-title":"Eur Heart J"},{"issue":"7","key":"1559_CR6","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","volume":"64","author":"MR Langlois","year":"2018","unstructured":"Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. Quantifying Atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus Statement from EAS and EFLM. Clin Chem. 2018;64(7):1006\u201333. https:\/\/doi.org\/10.1373\/clinchem.2018.287037.","journal-title":"Clin Chem"},{"issue":"7","key":"1559_CR7","doi-asserted-by":"publisher","first-page":"669","DOI":"10.5551\/jat.51961","volume":"27","author":"M Higashioka","year":"2020","unstructured":"Higashioka M, Sakata S, Honda T, Hata J, Yoshida D, Hirakawa Y, et al. Small dense low-density lipoprotein cholesterol and the risk of coronary heart disease in a Japanese community. J Atheroscler Thromb. 2020;27(7):669\u201382. https:\/\/doi.org\/10.5551\/jat.51961.","journal-title":"J Atheroscler Thromb"},{"issue":"11","key":"1559_CR8","doi-asserted-by":"publisher","first-page":"e0241993","DOI":"10.1371\/journal.pone.0241993","volume":"15","author":"L Liou","year":"2020","unstructured":"Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241993.","journal-title":"PLoS One"},{"issue":"1","key":"1559_CR9","first-page":"414","volume":"20","author":"R Duan","year":"2020","unstructured":"Duan R, Xue W, Wang K, et al. Estimation of the LDL subclasses in ischemic stroke as a risk factor in a Chinese population. BioMed Central Neurol. 2020;20(1):414.","journal-title":"BioMed Central Neurol"},{"key":"1559_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.cca.2021.06.012","volume":"520","author":"C Kanonidou","year":"2021","unstructured":"Kanonidou C. Small dense low-density lipoprotein: analytical review. Clin Chim Acta. 2021;520:172\u20138. https:\/\/doi.org\/10.1016\/j.cca.2021.06.012.","journal-title":"Clin Chim Acta"},{"issue":"7","key":"1559_CR11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/clinchem\/hvab048","volume":"67","author":"M Sampson","year":"2021","unstructured":"Sampson M, Wolska A, Warnick R, Lucero D, Remaley AT. A new equation based on the standard lipid panel for calculating small dense low-density lipoprotein-cholesterol and its use as a risk-enhancer test. Clin Chem. 2021;67(7):987\u201397. https:\/\/doi.org\/10.1093\/clinchem\/hvab048.","journal-title":"Clin Chem"},{"issue":"1","key":"1559_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-1182-5","volume":"19","author":"M Yu","year":"2020","unstructured":"Yu M, Liang C, Kong Q, Wang Y, Li M. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis. 2020;19(1):1.","journal-title":"Lipids Health Dis"},{"key":"1559_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2017.03.015","volume":"260","author":"RA Othman","year":"2017","unstructured":"Othman RA, Myrie SB, Mymin D, Roullet JB, Steiner RD, Jones PJH. Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia. Atherosclerosis. 2017;260:27\u201333. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.03.015.","journal-title":"Atherosclerosis"},{"issue":"6","key":"1559_CR14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.metabol.2008.01.026","volume":"57","author":"DL Tribble","year":"2008","unstructured":"Tribble DL, Farnier M, Macdonell G, Perevozskaya I, Davies MJ, Gumbiner B, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism. 2008;57(6):796\u2013801. https:\/\/doi.org\/10.1016\/j.metabol.2008.01.026.","journal-title":"Metabolism"},{"issue":"1","key":"1559_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2011.10.043","volume":"220","author":"K Winkler","year":"2012","unstructured":"Winkler K, Jacob S, M\u00fcller-Schewe T, Hoffmann MM, Konrad T. Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis. 2012;220(1):189\u201393.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1559_CR16","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1016\/j.clinthera.2007.10.004","volume":"29","author":"L Ose","year":"2007","unstructured":"Ose L, Reyes R, Johnson-Levonas AO, Sapre A, Tribble DL, Musliner T. Effects of ezetimibe\/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther. 2007;29(11):2419\u201332. https:\/\/doi.org\/10.1016\/j.clinthera.2007.10.004.","journal-title":"Clin Ther"},{"issue":"3","key":"1559_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1185\/03007995.2011.554809","volume":"27","author":"N Katsiki","year":"2011","unstructured":"Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Curr Med Res Opin. 2011;27(3):693\u20135.","journal-title":"Curr Med Res Opin"},{"issue":"13","key":"1559_CR18","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/eurheartj\/ehq181","volume":"31","author":"K Berneis","year":"2010","unstructured":"Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J. 2010;31(13):1633\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehq181.","journal-title":"Eur Heart J"},{"issue":"7","key":"1559_CR19","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1194\/jlr.M073882","volume":"58","author":"N Thongtang","year":"2017","unstructured":"Thongtang N, Diffenderfer MR, Ooi EMM, Barrett PHR, Turner SM, le NA, et al. Metabolism and proteomics of large and small dense LDL in combined hyperlipidemia: effects of rosuvastatin. J Lipid Res. 2017;58(7):1315\u201324. https:\/\/doi.org\/10.1194\/jlr.M073882.","journal-title":"J Lipid Res"},{"issue":"9670","key":"1559_CR20","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"PM Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJP, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(09)60447-5.","journal-title":"Lancet"},{"issue":"13","key":"1559_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","volume":"132","author":"EA Bohula","year":"2015","unstructured":"Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224\u201333. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018381.","journal-title":"Circulation"},{"issue":"9","key":"1559_CR22","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40261-020-00951-1","volume":"40","author":"AS Bhagavathula","year":"2020","unstructured":"Bhagavathula AS, Aldhaleei WA, Al Matrooshi NO, Rahmani J. Efficacy of statin\/Ezetimibe for secondary prevention of atherosclerotic cardiovascular disease in Asian populations: a systematic review and Meta-analysis of randomized controlled trials. Clin Drug Investig. 2020;40(9):809\u201326. https:\/\/doi.org\/10.1007\/s40261-020-00951-1.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"1559_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1186\/s13063-017-2361-1","volume":"18","author":"FAH Fonseca","year":"2017","unstructured":"Fonseca FAH, Izar MC, Maugeri IML, et al. Effects of four antiplatelet\/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial. Trials. 2017;18(1):601.","journal-title":"Trials"},{"issue":"2","key":"1559_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/clinchem\/47.2.266","volume":"47","author":"DM Hoefner","year":"2001","unstructured":"Hoefner DM, Hodel SD, O\u2019Brien JF, Branum EL, Sun D, Meissner I, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL system. Clin Chem. 2001;47(2):266\u201374. https:\/\/doi.org\/10.1093\/clinchem\/47.2.266.","journal-title":"Clin Chem"},{"issue":"12","key":"1559_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s11745-011-3611-8","volume":"46","author":"KA Varady","year":"2011","unstructured":"Varady KA, Lamarche B. Lipoprint adequately estimates LDL size distribution, but not absolute size, versus polyacrylamide gradient gel electrophoresis. Lipids. 2011;46(12):1163\u20137. https:\/\/doi.org\/10.1007\/s11745-011-3611-8.","journal-title":"Lipids"},{"issue":"12","key":"1559_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"issue":"11","key":"1559_CR27","doi-asserted-by":"publisher","first-page":"e012638","DOI":"10.1161\/JAHA.119.012638","volume":"8","author":"JJ Carrero","year":"2019","unstructured":"Carrero JJ, Franko MA, Obergfell A, Gabrielsen A, Jernberg T. hsCRP Level and the Risk of Death or Recurrent Cardiovascular Events in Patients With Myocardial Infarction: a Healthcare-Based Study. J Am Heart Assoc. 2019;8(11):e012638.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1559_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1373\/clinchem.2009.137489","volume":"56","author":"M Ai","year":"2010","unstructured":"Ai M, Otokozawa S, Asztalos BF, Ito Y, Nakajima K, White CC, et al. Small dense LDL cholesterol and coronary heart disease: results from the Framingham offspring study. Clin Chem. 2010;56(6):967\u201376. https:\/\/doi.org\/10.1373\/clinchem.2009.137489.","journal-title":"Clin Chem"},{"issue":"1","key":"1559_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1161\/ATVBAHA.113.302401","volume":"34","author":"MY Tsai","year":"2014","unstructured":"Tsai MY, Steffen BT, Guan W, McClelland RL, Warnick R, McConnell J, et al. New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34(1):196\u2013201. https:\/\/doi.org\/10.1161\/ATVBAHA.113.302401.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1559_CR30","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","volume":"34","author":"RC Hoogeveen","year":"2014","unstructured":"Hoogeveen RC, Gaubatz JW, Sun W, Dodge RC, Crosby JR, Jiang J, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014;34(5):1069\u201377. https:\/\/doi.org\/10.1161\/ATVBAHA.114.303284.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"1559_CR31","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.115.016857","volume":"132","author":"S Mora","year":"2015","unstructured":"Mora S, Caulfield MP, Wohlgemuth J, Chen Z, Superko HR, Rowland CM, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the justification for the use of statins in prevention: an intervention trial evaluating Rosuvastatin (JUPITER) trial. Circulation. 2015;132(23):2220\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.016857.","journal-title":"Circulation"},{"issue":"10","key":"1559_CR32","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","volume":"119","author":"A Baruch","year":"2017","unstructured":"Baruch A, Mosesova S, Davis JD, Budha N, Vilimovskij A, Kahn R, et al. Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study). Am J Cardiol. 2017;119(10):1576\u201383. https:\/\/doi.org\/10.1016\/j.amjcard.2017.02.020.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1559_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1476-511X-9-136","volume":"9","author":"H Bays","year":"2010","unstructured":"Bays H, Conard S, Leiter LA, Bird S, Jensen E, Hanson ME, et al. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis. 2010;9(1):136. https:\/\/doi.org\/10.1186\/1476-511X-9-136.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"1559_CR34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12967-015-0452-x","volume":"13","author":"RX Xu","year":"2015","unstructured":"Xu RX, Liu J, Li XL, Li S, Zhang Y, Jia YJ, et al. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms. J Transl Med. 2015;13(1):87. https:\/\/doi.org\/10.1186\/s12967-015-0452-x.","journal-title":"J Transl Med"},{"issue":"1","key":"1559_CR35","doi-asserted-by":"publisher","first-page":"15973","DOI":"10.1038\/s41598-021-95455-z","volume":"11","author":"A Klassen","year":"2021","unstructured":"Klassen A, Faccio AT, Picossi CRC, et al. Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction. Sci Rep. 2021;11(1):15973.","journal-title":"Sci Rep"},{"issue":"1","key":"1559_CR36","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12944-021-01475-z","volume":"20","author":"Y Xue","year":"2021","unstructured":"Xue Y, Shen J, Hong W, et al. Risk stratification of ST-segment elevation myocardial infarction (STEMI) patients using machine learning based on lipid profiles. Lipids Health Dis. 2021;20(1):48.","journal-title":"Lipids Health Dis"},{"key":"1559_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2017.09.019","volume":"266","author":"Y Pokharel","year":"2017","unstructured":"Pokharel Y, Sharma PP, Qintar M, Lu Y, Tang Y, Jones P, et al. High-sensitivity C-reactive protein levels and health status outcomes after myocardial infarction. Atherosclerosis. 2017;266:16\u201323. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2017.09.019.","journal-title":"Atherosclerosis"},{"issue":"10","key":"1559_CR38","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","volume":"45","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dl and C-reactive protein <2 mg\/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45(10):1644\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2005.02.080.","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"1559_CR39","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","volume":"39","author":"PM Ridker","year":"2018","unstructured":"Ridker PM, Libby P, MacFadyen JG, Thuren T, Ballantyne C, Fonseca F, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Eur Heart J. 2018;39(38):3499\u2013507. https:\/\/doi.org\/10.1093\/eurheartj\/ehy310.","journal-title":"Eur Heart J"},{"issue":"26","key":"1559_CR40","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med"},{"issue":"42","key":"1559_CR41","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","volume":"41","author":"N Bouabdallaoui","year":"2020","unstructured":"Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Eur Heart J. 2020;41(42):4092\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa659.","journal-title":"Eur Heart J"},{"issue":"22","key":"1559_CR42","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"2","key":"1559_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","volume":"138","author":"EA Bohula","year":"2018","unstructured":"Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation. 2018;138(2):131\u201340. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034032.","journal-title":"Circulation"},{"issue":"2","key":"1559_CR44","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/03007995.2016.1252740","volume":"33","author":"AC Sposito","year":"2017","unstructured":"Sposito AC, Faria Neto JR, Carvalho LS, Lorenzatti A, Cafferata A, Elikir G, et al. Statin-associated muscle symptoms: position paper from the Luso-Latin American consortium. Curr Med Res Opin. 2017;33(2):239\u201351. https:\/\/doi.org\/10.1080\/03007995.2016.1252740.","journal-title":"Curr Med Res Opin"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01559-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01559-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01559-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T17:19:04Z","timestamp":1632935944000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01559-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1559"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01559-w","relation":{},"ISSN":["1476-511X"],"issn-type":[{"type":"electronic","value":"1476-511X"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"3 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the local ethics committee (Escola Paulista de Medicina \u2013 UNIFESP IRB 0297\/2014; CAAE: 71652417.3.0000.5505), which follows the latest Declaration of Helsinki, and written informed consent was provided by all patients before their inclusion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consented to publish the results shown.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. FAH Fonseca declares receiving consulting fees from NovoNordisk, Novartis, and AstraZeneca, lecture fees from Novo Nordisk, Abbott, Ache, Biolab, Libbs, Ely Lilly, Sanofi Aventis, Amgen, and AstraZeneca, and travel support from Amgen, Bayer and NovoNordisk. MC Izar declares receiving consulting fees from Amgen, PTC, Amryt Pharma, Novartis, lecture fees from Amgen, PTC, Libbs, Ache, and travel support from Novo Nordisk and Amgen. The authors have no additional relevant financial or nonfinancial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}